An open-label 16-week study of liraglutide in adolescents with obesity post-sleeve gastrectomy.

ABSTRACT:

Background

Up to 50% of adolescents who undergo metabolic and bariatric surgery (MBS) have obesity 3 years post-MBS, placing them at continued risk for the consequences of obesity.

Objectives

We conducted an open-label, 16-week pilot study of liraglutide in adolescents with obesity after sleeve gastrectomy (SG) to investigate liraglutide effects on weight and body mass index (BMI) post-SG.

Methods

Adolescents aged 12-20.99 years with obesity and a history of SG ≥1 year prior were enrolled. Liraglutide was initiated at 0.6 mg/day, escalated weekly to a maximum of 3 mg/day, with treatment duration 16 weeks. Fasting laboratory assessments and an oral glucose tolerance test were performed at baseline and end-treatment.

Results

A total of 43 participants were screen

SUBMITTER: Zenno A 

PROVIDER: S-EPMC11486571 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature